Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Rezpegaldesleukin · NKTR-358, LY-3471851

Fusion protein · developed by Nektar Therapeutics

Phase 3 Most advanced trial
NKTR Developer
2 Registered trials

What is Rezpegaldesleukin?

Rezpegaldesleukin is an injectable subcutaneous drug studied in moderate-to-severe atopic dermatitis and systemic lupus erythematosus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NKTR-358, LY-3471851, REZPEG
Drug type
Fusion protein
Therapy area
Immunology
Developer
Nektar Therapeutics (NKTR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
VGR86P26ER

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07711418 Phase 3 Moderate-to-Severe Atopic Dermatitis Recruiting NKTR
NCT04433585 Phase 2 Systemic Lupus Erythematosus Completed NKTR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Moderate-to-Severe Atopic DermatitisSystemic Lupus Erythematosus

More from Nektar Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NKTR page.

Follow NKTR, the company behind Rezpegaldesleukin

See NKTR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NKTR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.